Development of a new platform technology for efficient, fast and cost-effective antibody generation.
The consortium will deliver an innovative platform technology including bioinformatics tools for the selection, characterization and production of monoclonal antibodies (mAbs), integrating mass spectrometry, next generation sequencing and bioinformatics tools. The resulting EffiBody platform technology will be more reliable, faster and cost-effective than current methods, ensuring high competitiveness on market. To achieve Proof of Concept, mAbs against cancer targets will be generated.
3 363 090.00€
Enzymology / Protein Engineering / Fermentation
Monoclonal Antibodies and Hybridomas